ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2018
Advances in Serodiagnostic Testing for Lyme Disease Are at Hand.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 1 synthesis or guideline pooled it, 106 citations in OpenAlex.
- Global seroprevalence and sociodemographic characteristics ofBMJ global health · 2022Pooled it
- Dynamics of Borrelial Antibodies in European Lyme Borreliosis Patients with Erythema Migrans.Medical sciences (Basel, Switzerland) · 2026Article
- Article
- Evaluation of standard and modified two-tiered testing algorithms using well-characterized early Lyme disease samples.Journal of clinical microbiology · 2026Article
- Ticks and tick-borne diseases: A call for comprehensive tick surveillance in India under One Health approach.The Indian journal of medical research · 2026Review
- Interlaboratory Concordance of a Multiplex ELISA for Lyme and Lyme-like Illness Using Australian Samples and Commercial Reference Panels: A Proof-of-Concept Study.Pathogens (Basel, Switzerland) · 2025Article
- Class and isotype of VlsE-specific antibody differentiates Lyme disease stage.Journal of clinical microbiology · 2025Article
- Proposed research classification criteria for Lyme disease in infection associated chronic illness studies.Frontiers in medicine · 2025Article
- Real-world Lyme disease testing results using modified vs standard two-tier test protocols.PloS one · 2025Article
- Borrelia PeptideAtlas: A proteome resource of common Borrelia burgdorferi isolates for Lyme research.Scientific data · 2024Article
- Synovial fluid alpha-defensins in Lyme arthritis-a useful marker.Folia microbiologica · 2024Article
- Rapid single-tier serodiagnosis of Lyme disease.Nature communications · 2024Article
- Meningitis in the Guise of Dementia: Lyme-Induced Normal Pressure Hydrocephalus.Clinical medicine & research · 2023Review
- Lyme borreliosis diagnosis: state of the art of improvements and innovations.BMC microbiology · 2023Review
- Common Neurologic Features of Lyme Disease That May Present to a Rheumatologist.Pathogens (Basel, Switzerland) · 2023Article
- Initial Presentation and Time to Treatment in Early Lyme Disease.The American journal of tropical medicine and hygiene · 2023Article
- Multiplex High-Definition Polymerase Chain Reaction Assay for the Diagnosis of Tick-borne Infections in Children.Open forum infectious diseases · 2023Article
- Profiling disease burden and Borrelia seroprevalence in Canadians with complex and chronic illness.PloS one · 2023Article
- Improving Lyme disease testing with data driven test design in pediatrics.Journal of pathology informatics · 2023Article
- The Spectrum of Erythema Migrans in Early Lyme Disease: Can We Improve Its Recognition?Cureus · 2022Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 18 institutions in 1 country.
Funding
Abstract
The cause of Lyme disease, Borrelia burgdorferi, was discovered in 1983. A 2-tiered testing protocol was established for serodiagnosis in 1994, involving an enzyme immunoassay (EIA) or indirect fluorescence antibody, followed (if reactive) by immunoglobulin M and immunoglobulin G Western immunoblots. These assays were prepared from whole-cell cultured B. burgdorferi, lacking key in vivo expressed antigens and expressing antigens that can bind non-Borrelia antibodies. Additional drawbacks, particular to the Western immunoblot component, include low sensitivity in early infection, technical complexity, and subjective interpretation when scored by visual examination. Nevertheless, 2-tiered testing with immunoblotting remains the benchmark for evaluation of new methods or approaches. Next-generation serologic assays, prepared with recombinant proteins or synthetic peptides, and alternative testing protocols, can now overcome or circumvent many of these past drawbacks. This article describes next-generation serodiagnostic testing for Lyme disease, focusing on methods that are currently available or near-at-hand.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.